Investing in Biotech - A Guide to Risk-Return Analysis with Valuation Techniques

A growing attention to the Biotech sector has been shown in the accelerating investments by Venture Capital funds and IPOs, as well as the expectation of innovative therapies amidst Covid-19. This article, therefore, provides a guide on Biotech investment analysis with highlighting the “3H” characteristics of Biotech industry—High inputs in R&D, High Rewards, and High Risks, and demonstrating related valuation approaches for quantitative analysis.

 

Click here to read the full article.

 

 

Meet Our People

VINCENT PANG

VINCENT PANG

Managing Director

AVISTA GROUP

vincent.pang@avaval.com

HAILEY JIN

HAILEY JIN

Director

VALUATION ADVISORY

hailey.jin@avaval.com

IVAN LUI

IVAN LUI

Director

VALUATION ADVISORY

ivan.lui@avaval.com

Date: 04 Feb 2021 | Tags: Business Valuation, Initial Public Offering (IPO), Financial Reporting, Corporate Transaction

Privacy & Disclaimer

© COPYRIGHT 2020 AVISTA GROUP, ALL RIGHTS RESERVED

沪ICP备17054339号